ubmslateOT-logo-ubm

OT mobile menu

Search form

Topics:

Home

New Data Confirm Clinical Benefit of Project GENIE

Project GENIE links cancer genomic data with clinical outcomes from tens of thousands of cancer patients treated at multiple institutions. Image © Dmitry Kalinovsky/Shutterstock.com

Recent Content

Adding the PARP inhibitor veliparib to carboplatin and paclitaxel chemotherapy regimens failed to prolong overall survival in lung and breast cancers.

Mateusz Opyrchal, MD, PhD, talks about his study on the Inhibition of AURKA induces Raf1-independent activation of MAPK pathway in breast cancer cells.

Using state-of-the-art gene editing technology, researchers have discovered a promising target to treat atypical teratoid/rhabdoid tumor (AT/RT), a highly aggressive and therapy-resistant brain tumor.

In this video, Michael Ciesielski, PhD, of Roswell Park Cancer Institute in Buffalo, talks about circulating exosomes isolated from the serum of malignant glioma patients enrolled in a completed phase I clinical trial of an anti-survivin vaccine (SurVaxM).

A 27-year-old African American man presents with a soft tissue lesion in his right chest. After a biopsy is performed, what is your diagnosis?

Kinase oncoproteins and growth factors both activate the proto-oncogene c-FOS and DUSP1, allowing the persistence of residual leukemia cell populations despite tyrosine kinase inhibitor therapy.

In this video, David Goodrich, PhD, of Roswell Park Cancer Institute in Buffalo, discusses treatment resistance and disease relapse in prostate cancer.

By clicking Accept, you agree to become a member of the UBM Medica Community.